| 摘要: |
| ［摘要］ 三阴性乳腺癌(TNBC)是一类强异质性的乳腺恶性肿瘤，具有不同于其他类型乳腺癌的独特生物学特征及病理学特征，其雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体-2(HER-2)的免疫组化标记均为阴性。由于其缺乏相应的激素受体和HER-2表达，TNBC早期和术后的主要治疗方法为含蒽环类和紫杉类药物的新辅助化疗，但对于已发生复发或转移的患者仍缺乏有效的治疗方案，故TNBC的治疗仍是医学界的难题。该文对TNBC的治疗研究进展作一综述。 |
| 关键词: 三阴性乳腺癌 亚型 耐药性 靶点 免疫疗法 |
| DOI：10.3969/j.issn.1674-3806.2020.12.25 |
| 分类号:R 737 |
| 基金项目: |
|
| Advances in therapeutic research of triple-negative breast cancer |
|
WANG Li-zhi, XING Xiao-jing
|
|
China Medical University, Shenyang 110122, China
|
| Abstract: |
| ［Abstract］ Triple-negative breast cancer(TNBC) is a highly heterogeneous breast cancer with unique biological and pathological characteristics different from other types of breast cancer. Its immunohistochemical markers of estrogen receptor(ER), progesterone receptor(PR) and human epidermal growth factor receptor 2(HER-2) are all negative.Due to the lack of the corresponding hormone receptors and HER-2 expression, up to now, the main early and postoperative treatment of TNBC is neoadjuvant chemotherapy containing anthracyclines and taxanes. However, there is still no effective treatment plan for the patients with recurrence or metastasis of TNBC, so the treatment of TNBC is still a thorny problem in the medical field. In this paper, the research progress in the treatment of TNBC is reviewed. |
| Key words: Triple-negative breast cancer(TNBC) Subtypes Drug resistance Targets Immunotherapy |
